Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureKonstantinos Karampatsas, Eve Nakabembe
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
2025
Waning protection after fifth dose of acellular pertussis vaccine in children
10.1056/nejmoa1200850 · 2012
Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model
10.1073/pnas.1314688110 · 2014
Unresolved referenced work
2026
Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015
10.2807/1560-7917.es.2019.24.7.1700832 · 2019
Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus–diphtheria–acellular pertussis vaccine: a randomised, double-blind, phase 2b trial
10.1016/s0140-6736(22)02644-7 · 2023
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis
10.1016/j.lanmic.2025.101211 · 2025
IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine
10.1038/s41385-018-0073-9 · 2018
An alternative route to pertussis protection?
10.1016/s0140-6736(23)00225-8 · 2023
The potential public health benefit of live-attenuated pertussis vaccines
10.1080/17425247.2025.2590740 · 2026
No additional external references are available.